WallStreetZenWallStreetZen

NASDAQ: EXAS
Exact Sciences Corp Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

EXAS past revenue growth

How has EXAS's revenue growth performed historically?
Company
19.93%
Industry
0.14%
Market
16.96%
EXAS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EXAS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EXAS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EXAS earnings and revenue history

Current Revenue
$2.5B
Current Earnings
-$204.1M
Current Profit Margin
-8.2%

EXAS Return on Equity

Current Company
-6.6%
Current Industry
-24%
Current Market
188%
EXAS's Return on Equity (-6.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when EXAS announces earnings.

EXAS Return on Assets

Current Company
-3.2%
Current Industry
6.7%
EXAS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

EXAS Return on Capital Employed

Current Company
-3.06%
Current Industry
11.6%
EXAS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EXAS vs Diagnostic & Research Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
EXAS$2.50B$52.20M-$204.15M+40.63%N/A
NTRA$1.08B-$383.28M-$434.80M+33.26%N/A
CRL$4.13B$1.03B$474.62M+12.75%+14.45%
MEDP$1.96B$405.89M$312.51M+21.47%+36.07%
RVTY$2.75B$1.25B$693.09M-0.20%+20.93%
View Top Diagnostic & Research Stocks

EXAS earnings dates

Next earnings date
May 8, 2024

Exact Sciences Earnings & Revenue FAQ

What were EXAS's earnings last quarter?

On Invalid Date, Exact Sciences (NASDAQ: EXAS) reported Q4 2023 earnings per share (EPS) of -$0.27, up 62.5% year over year. Total Exact Sciences earnings for the quarter were -$49.77 million. In the same quarter last year, Exact Sciences's earnings per share (EPS) was -$0.72.

If you're new to stock investing, here's how to buy Exact Sciences stock.

What was EXAS's earnings growth in the past year?

As of Q2 2024, Exact Sciences's earnings has grown year over year. Exact Sciences's earnings in the past year totalled -$204.15 million.

What is EXAS's earnings date?

Exact Sciences's earnings date is Invalid Date. Add EXAS to your watchlist to be reminded of EXAS's next earnings announcement.

What was EXAS's revenue last quarter?

On Invalid Date, Exact Sciences (NASDAQ: EXAS) reported Q4 2023 revenue of $646.89 million up 16.98% year over year. In the same quarter last year, Exact Sciences's revenue was $553.00 million.

What was EXAS's revenue growth in the past year?

As of Q2 2024, Exact Sciences's revenue has grown 19.93% year over year. This is 19.79 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 0.14%. Exact Sciences's revenue in the past year totalled $2.50 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.